Prediction of major bleeding events by using CRUSADE and ACUITY risk scores in cohort of Chinese ticagrelor-treated patients with acute coronary syndrome after PCI

Trial Profile

Prediction of major bleeding events by using CRUSADE and ACUITY risk scores in cohort of Chinese ticagrelor-treated patients with acute coronary syndrome after PCI

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Ticagrelor (Primary)
  • Indications Acute coronary syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Oct 2017 New trial record
    • 10 Oct 2017 Results published in the Thrombosis and Haemostasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top